BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
51.94
-0.02 (-0.04%)
At close: Sep 30, 2025, 4:00 PM EDT
51.93
-0.01 (-0.02%)
After-hours: Sep 30, 2025, 4:40 PM EDT
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 16 analysts that cover BridgeBio Pharma stock have a consensus rating of "Strong Buy" and an average price target of $64.44, which forecasts a 24.07% increase in the stock price over the next year. The lowest target is $46 and the highest is $95.
Price Target: $64.44 (+24.07%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 7 | 7 | 7 |
| Buy | 6 | 6 | 8 | 9 | 9 | 9 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 14 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +34.77% | Sep 15, 2025 |
| UBS | UBS | Strong Buy Maintains $72 → $82 | Strong Buy | Maintains | $72 → $82 | +57.87% | Sep 12, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $55 → $70 | Buy | Maintains | $55 → $70 | +34.77% | Sep 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +34.77% | Sep 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $56 → $70 | Strong Buy | Maintains | $56 → $70 | +34.77% | Aug 29, 2025 |
Financial Forecast
Revenue This Year
479.24M
from 221.90M
Increased by 115.97%
Revenue Next Year
793.14M
from 479.24M
Increased by 65.50%
EPS This Year
-3.45
from -2.88
EPS Next Year
-2.12
from -3.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 572.4M | 1.2B | |||
| Avg | 479.2M | 793.1M | |||
| Low | 403.8M | 525.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 157.9% | 146.2% | |||
| Avg | 116.0% | 65.5% | |||
| Low | 82.0% | 9.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.21 | -0.67 | |||
| Avg | -3.45 | -2.12 | |||
| Low | -3.79 | -3.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.